Patrick Brunner Email & Phone Number

Copenhagen, DK

Currently embedded in the North American business unit, supporting Xellia’s focus on injectable product technologies and its position as a world-leading supplier of important established anti-infective drugs. Lead more than 350 employees in manufacturing as we fulfill the company ambition of providing US hospitals and patients with critical care products.

Performed due diligence to support several pharmaceutical acquisitions, most notably on biologics and API facilities and a women’s health company based in the UK. Currently vetting a facility in Serbia for purchase by a company in Europe. Among other experiences, advice is informed by unique expertise gained at Actavis, Teva, and Watson in manufacturing.

London, GB

Successfully acquired a women’s health product line and converted it into the foundation of a new pharmaceutical company, seamlessly transferring ownership of over 1200 Marketing Authorizations with minimal waste and out-of-stocks. In just 9 months, secured the infrastructure and licenses necessary to support first year net sales of 230M Euros..

Dublin, IE

Led the Watson/Actavis network rationalization that produced over $400M in synergies and savings from the closure of 9 facilities in Europe and Asia. Identified 3 overseas sights with the possibility of being granted FDA approval and worked through the steps needed to secure that credential. Instituted processes that transferred manufacturing to lower cost.

Responsible for due diligence and optimization of key acquisitions, including Arrow Labs, Specifar, Drug Houses Australia, Actavis, Odyssea, and Warner Chilcott. Proactively created a playbook that supported go-no-go decision making, standardization of activities necessary for effective integration, and a risk/rewards assessment at the Board of Directors.

Initiated and implemented a worldwide operational excellence program that maintained service levels above 95% and improved safety to <.5 LTIR at all sights. Spearheaded a procurement bidding process that resulted in > $150 million in API and outsourced finished goods cost savings, while consolidating the existing vendor base by 20%.

Tel-Aviv, IL

Member of the IPI’s President's Executive Leadership Team, which established, led, and executed strategic objectives that elevated the company from top 10 to #5 among its pharmaceutical peers. Championed operational initiatives for the Product Launch Team, helping to grow the portfolio from 30 to over 175 molecules in less than 10 years. In 2006, directed.